rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GNBT !!!

2.656 Posts
Pagina: 1 2 3 4 5 6 ... 133 »» | Laatste | Omlaag ↓
  1. Bel-chin 22 juni 2005 14:39

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    Generex Biotechnology Corporation (ticker: GNBT, exchange: NASDAQ Stock Exchange (.O)) News Release - 22-Jun-2005
    Generex Biotechnology Begins Research Collaboration on Novel Allergy Therapy With Major European Company

    Stallergenes, a Principal European Allergy Firm Near Paris, Tests Novel

    Approach to Immunotherapy of Allergy and Asthma Designed by Antigen Express

    TORONTO, June 22 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT) today announced that a Research Collaboration Agreement has been signed by its subsidiary Antigen Express, Inc. with Stallergenes, S.A. a major European firm in immunological treatments for allergy and asthma.

    The studies are to design and test Ii-Key/allergen epitope hybrid peptides to create a novel approach for the control of both dangerous forms of asthma and functionally disabling allergic reactions. A large number of individuals in both North America and Europe suffer from various forms of allergic responses. These range from allergic rhinitis to cat dander, to ragweed hayfever, to potentially fatal asthmatic attacks from bee sting or peanut allergens.

    Antigen Express scientists have discovered that a segment of the immunoregulatory protein called Ii, acts on the HLA-DR molecules, which present antigenic peptide epitopes of allergens to T regulatory lymphocytes. By coupling this Ii-Key peptide covalently to the antigenic epitope peptides, the potency of the HLA-DR presented epitope is increased about 200 times in cell culture experiments and about 8 to 10 times after injecting animals.

    Allergists have been seeking a method to stimulate T helper cells in a manner that directs the immune response away from the allergic pattern. Allergy symptoms arise when a T helper cell type 2 (TH2) response occurs to an environmental antigen, stimulating production of immunoglobulin E (IgE). When IgE is crosslinked by recognition of an allergen protein, on the surface of mast cells and basophils, histamine and other mediators of allergy are released. A wide range of responses can be found ranging from local redness and swelling in the skin, itchy nose, ears, roof of mouth, watery eyes and sneezing, to severe bronchoconstriction requiring powerful medicines and potentially intubation and respiratory support.

    Antigen Express scientists have found that their established approach to stimulating responses to cancer and infectious disease antigens stimulates a strong TH1 response, away from a TH2 response. That is exactly the pattern sought in research studies to tune down allergic reactions. This method of treatment goes directly to the cause of the allergic response, rather than just treatment of symptoms.

    "Since my days in the Allergy Clinic of the Bethesda Naval Hospital, trying to help patients with moderate to severe forms of allergy and asthma, I have followed the scientific and clinical literature toward making some better product," said Robert Humphreys, M.D., Ph.D., the Chief Scientific Officer of Antigen Express. He feels now that he might just have that better product to control allergic reactions. Nevertheless, "A lot of work lies ahead, in collaboration with skilled researchers and clinicians working in allergy."

    In collaboration with Dr. Philippe Moingeon, Director of Research and Development at Stallergenes, Dr. Humphreys has designed a series of

    Ii-Key/allergic epitope hybrid peptides for assays in France, using both lymphocytes from allergic patients and in mouse animal models. Dr. Moingeon said, "Bob Humphreys has developed a novel approach to controlling allergy. We seek to test it further in the laboratory, to see if basic biological mechanisms support further work toward clinical trials. Potential advantages lie in the use of peptide fragments of the allergen, not recognized by IgE, and in the enhanced potency of the epitope so that therapy can be at very small doses."

    About Generex

    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral- lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Generex acquired Antigen Express in August, 2003. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

    For more information, visit the Generex Web site at www.generex.com.

    Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

    SOURCE Generex Biotechnology Corporation
    -0- 06/22/2005
  5. Bel-chin 22 juni 2005 14:47

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    quote:

    nika0 schreef:

    40k inderdaad al... dat had ik niet verwacht met dit nieuws... GNBT... ik zal het nooit gaan begrijpen ;)
    oeps ... en nu teruggezakt naar 0.77 :(
  7. Henk Snaph 22 juni 2005 14:49

    • Henk Snaph

      Lid sinds: 11 okt 2000

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 952

      Gegeven: 634

    •    Aantal posts: 10.940

    quote:

    Bel-chin schreef:

    [quote=nika0]
    40k inderdaad al... dat had ik niet verwacht met dit nieuws... GNBT... ik zal het nooit gaan begrijpen ;)
    [/quote]

    oeps ... en nu teruggezakt naar 0.77 :(
    Ik verwacht vandaag een hoge omzet met grote koersverschillen. Heb er alle vertrouwen in.

    Henks
  9. [verwijderd] 22 juni 2005 14:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    @toth@ schreef:

    en ik maar kijken naar gtcb, zat ik dus fout?
    nou..gtcb heeft de strijd om de 1$ ruimschoots gewonnen een tijd terug..
    gtcb en gnbt lagen toen nek aan nek boven in de 0.88 - 0.90
    gisteren close: gtcb 1.81 en gnbt 0.71 trek je conclusies ;)
    maar bij gnbt valt nog wel lekker veel winst te halen :D :D
  13. Bel-chin 22 juni 2005 14:57

    • Bel-chin

      Lid sinds: 23 mrt 2005

      Laatste bezoek: 06 jun 2024

    • Aanbevelingen

      Ontvangen: 2

      Gegeven: 6

    •    Aantal posts: 188

    quote:

    nika0 schreef:

    40k inderdaad al... dat had ik niet verwacht met dit nieuws... GNBT... ik zal het nooit gaan begrijpen ;)
    voor alle duidelijkheid: die 0.85 was maar 1k

    Pre-Market
    Time (ET) Pre-Market
    Price Pre-Market
    Share Volume
    08.45 $ 0.77 500
    08.33 $ 0.85 1000
    08.33 $ 0.80 330
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.33 $ 0.80 400
    08.33 $ 0.80 100
    08.32 $ 0.78 2700
    08.32 $ 0.78 300
    08.32 $ 0.78 2000
    08.32 $ 0.78 1930
    08.32 $ 0.78 2500
    08.32 $ 0.80 570
    08.32 $ 0.78 10000
    08.30 $ 0.78 100
    08.30 $ 0.77 2400
    08.30 $ 0.77 2500
    08.30 $ 0.78 1000
    08.30 $ 0.78 2500
    08.30 $ 0.76 1500
    08.30 $ 0.76 2500
  15. [verwijderd] 22 juni 2005 15:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    0.75 en boekje ziet er niet heel veelbelovend uit..
    hopen dat we op 0.75 kunnen sluiten en dat de stijgende trend daarmee weer opgepakt wordt...
  17. Henk Snaph 22 juni 2005 16:20

    • Henk Snaph

      Lid sinds: 11 okt 2000

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 952

      Gegeven: 634

    •    Aantal posts: 10.940

    quote:

    spyfly schreef:

    Laatste 0,70
    Laatste volume 1.000
    Tijd 16:17
    +/- -0,01 -1,41%
    Volume 139.146

    Narigheid...
    Boompje schudden.

    Henks
  18. [verwijderd] 22 juni 2005 16:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    De nieuwe wijze van allergieonderdrukking van Antigen Express verkeert nog in het academische stadium. In de verre toekomst(gezien de positie van Generex) mogelijk erg succesvol, maar waar is financiele instroom om deze projecten te trekken. Ik blijf gewoon zitten met mijn stukken en hoop er het beste van.
  19. [verwijderd] 22 juni 2005 16:24

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    toch ongelovelijk dat de koers steeds maar niet omhoog wil.. flinke laat drukt erop nu.. betwijfel het of we boven het slot van gisteren sluiten..

    and there's another black (red) candle
  21. Henk Snaph 22 juni 2005 16:28

    • Henk Snaph

      Lid sinds: 11 okt 2000

      Laatste bezoek: 03 mei 2023

    • Aanbevelingen

      Ontvangen: 952

      Gegeven: 634

    •    Aantal posts: 10.940

    quote:

    nika0 schreef:

    als we nou op 0.77 zouden kunnen sluiten krijgen we een mooie witte hamer ;)
    Men probeert gewoon mensen nerveus te maken. Zodra de boom leeggeschud is stijgt de koers vanzelf. De pb's die ze gegeven hebben blijven echt niet onbemerkt. Logisch, als een grote jongen in wil stappen, dat hij dat zo laag mogelijk doet. Ik blijf gewoon zitten.

    Henks

2.656 Posts
Pagina: 1 2 3 4 5 6 ... 133 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.106
AB InBev 2 5.535
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.103
ABO-Group 1 23
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.836
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.813
Aedifica 3 926
Aegon 3.258 323.051
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.903
Agfa-Gevaert 14 2.062
Ahold 3.538 74.349
Air France - KLM 1.025 35.275
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.205
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.776
AMG 971 134.269
AMS 3 73
Amsterdam Commodities 305 6.744
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 495
Antonov 22.632 153.605
Aperam 92 15.053
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.802
Arcelor Mittal 2.034 320.951
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.599
ASML 1.766 109.860
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.881
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449